What the Clinical Evidence Shows While large-scale randomized controlled trials specifically measuring testosterone as a primary endpoint in tirzepatide users are still emerging, the available evidence is encouraging: The SURMOUNT trials demonstrated average weight losses of 15-22.5% of body weight, a degree of fat reduction strongly associated with testosterone recovery in men with obesity-related hypogonadism (Jastreboff et al., 2022, NEJM )
By subscribing, you agree to our Terms of Service and Privacy Policy
Medicaid Coverage by State Medicaid coverage for weight loss medication varies dramatically by state, and this variability is one of the most significant equity issues in obesity medicine
This raises the possibility that GLP-1s could influence the gut-immune axis, which is often disrupted in autoimmune diseases
How Fallbrook Medical Center can help Constipation can be manageable with the right plan
That's why so many are turning to this unique model in 2025, as it aligns with the broader lifestyle overhaul consumers are seeking